Somatic mutations of OGFR identified in human cancers have been shown to disrupt nuclear trafficking of the receptor and attenuate the growth-suppressive response to OGF, indicating that alterations in OGFR structure directly influence cancer cell proliferation and therapeutic sensitivity [32]. This evidence concerns the gene PENK and cancer.